By Fineline Cube 
Pfizer China (NYSE: PFE) announced on August 11, 2025, an organizational optimization of its Oncology and Rare Disease Business Units. This restructuring aims to enhance focus and efficiency in critical treatment areas.
Hematology and Rare Disease Reorganization
The company has reorganized into two key business units:
- BG&H Franchise: Led by Chi Wang, this unit combines hematological oncology with breast and urogenital oncology. It focuses on treatments for blood, breast, and urogenital system cancers.
- RD Franchise: Led by Guangping Gu, this unit integrates the hemophilia and ATTR teams. It aims to accelerate the introduction and implementation of innovative products for rare disease treatments.
Lung Cancer Treatment Business
The lung cancer treatment business will optimize its regional layout and resource allocation. It will concentrate on three key regions: North China, South China, and East China, to drive sustained growth. Jihua Wang will continue to lead this area.
Implementation Timeline
The new organizational structure took effect on August 11, 2025. The lung cancer treatment structure will be implemented starting September 1, 2025.-Fineline Info & Tech